Register Login

SYNLOGIC, INC. (SYBX)

SymbolSYBX
NameSYNLOGIC, INC.
SectorHEALTH CARE
RegionNorth America
Industry-
Address01890 United States MA PO Box 30
Telephone(617) 659-2802
Fax—
Email—
Websitehttps://www.synlogictx.com/
IncorporationUS
Incorporated On2007
Employees—
Fiscal Year12/31
Public Since—
ExchangesOTC;NASDAQ
AuditorKPMG LLP - New York, New York, (USA);
Audit StatusAUDITED
Reporting StatusU.S. Reporting: SEC Reporting
CIK0001527599
Description

We are a biopharmaceutical company that advanced novel therapeutics to transform the
care of serious diseases. We focused on rare metabolic disorders, with our lead program,
labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase
3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment
for homocystinuria (HCU).

Additional info from OTC:
We are a biopharmaceutical company that advanced novel therapeutics to transform the
care of serious diseases. We focused on rare metabolic disorders, with our lead program,
labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase
3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment
for homocystinuria (HCU).

Additional info from NASDAQ:
Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines which are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the companys proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects.

2026-01-29 11:15

New Form 8-K/A - SYNLOGIC, INC. <b>Filed:</b> 2026-01-29 <b>AccNo:</b> 0001193125-26-028333 <b>Size:</b> 173 KB <br />Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing <br />Item 8.01: Other Events

Read more
2026-01-21 09:10

Synlogic Inc. (SYBX) was removed from the list of traded instruments on NASDAQ exchange

Read more
2026-01-21 08:22

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Synlogic, Inc. - Common Stock.

Read more
2026-01-21 08:22

NASDAQ symbol attribute type Security_Name was changed. Previous value: Synlogic, Inc. - Common Stock. New value: Synlogic, Inc. - Common Stock.

Read more
2026-01-21 08:22

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Synlogic, Inc. - Common Stock.

Read more
2026-01-21 02:47

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Read more
2026-01-21 00:51

NASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: Synlogic, Inc. - Common Stock.

Read more
2026-01-21 00:51

NASDAQ traded attribute type Security_Name was changed. Previous value: Synlogic, Inc. - Common Stock. New value: Synlogic, Inc. - Common Stock.

Read more
2026-01-21 00:51

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: Synlogic, Inc. - Common Stock.

Read more
2026-01-20 19:26

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Read more